 | Symposium slides and videos now available
|
|  | 
Thank you to all of the presenters, sponsors, and engaged attendees who made the Nov. 16 V-BID Center symposium a great success. It was an exciting and thought-provoking day, and we look forward to the continued collaboration. Our post-event website is a complete resource with videos and slides from all sessions.
|
| V-BID benefit shown in New England Journal of Medicine
|
|
| |
A study by Harvard's Niteesh Choudhry, MD PhD, published in The New England Journal of Medicine showed that eliminating co-payments for post-heart attack medications increased medication adherence modestly, improved patient health, and had little overall impact on costs.
With the co-pays eliminated, medication adherence improved 4-6%, patients saved about $500 each, costs to the health plan changed little, and there were fewer major vascular events.
Read article commentary
Read WSJ coverage
|
| New V-BID products launched
|
| | Based on the findings of the New England Journal of Medicine study above, Aetna has launched a new value-based program focusing on lowering barriers to high-value medications for members that have suffered from heart attacks.
SeeChange Health launched a new Administrative Services Only value-based product for self-insured employers in all 50 states. SeeChange notes that this product is in response to increasing demand from employers for cost controls derived from value-based approaches.
|
| Center testimony at US Senate Committee
|
| |
The V-BID Center's A. Mark Fendrick, MD, testified at the US Senate Committee on Health, Education, Labor and Pensions on Nov. 10. The testimony described the role of V-BID in healthcare delivery innovation and the emergence of clinically-nuanced approaches as a means to improve health outcomes and 'bend the cost curve.'
|
| | |
From all of us at the V-BID Center, we wish you a joyous holiday season and all the best in the year ahead. Happy Holidays!
|
